U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    35,698.63
    +205.00 (+0.58%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Roche Holding AG Stock Is Believed To Be Fairly Valued

·4 min read

- By GF Value

The stock of Roche Holding AG (OTCPK:RHHBY, 30-year Financials) is estimated to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $41.2 per share and the market cap of $281.2 billion, Roche Holding AG stock appears to be fairly valued. GF Value for Roche Holding AG is shown in the chart below.


Roche Holding AG Stock Is Believed To Be Fairly Valued
Roche Holding AG Stock Is Believed To Be Fairly Valued

Because Roche Holding AG is fairly valued, the long-term return of its stock is likely to be close to the rate of its business growth, which averaged 2.8% over the past three years and is estimated to grow 2.48% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. Roche Holding AG has a cash-to-debt ratio of 0.80, which is in the middle range of the companies in Drug Manufacturers industry. The overall financial strength of Roche Holding AG is 6 out of 10, which indicates that the financial strength of Roche Holding AG is fair. This is the debt and cash of Roche Holding AG over the past years:

Roche Holding AG Stock Is Believed To Be Fairly Valued
Roche Holding AG Stock Is Believed To Be Fairly Valued

It poses less risk to invest in profitable companies, especially those that have demonstrated consistent profitability over the long term. A company with high profit margins is also typically a safer investment than one with low profit margins. Roche Holding AG has been profitable 10 over the past 10 years. Over the past twelve months, the company had a revenue of $63.5 billion and earnings of $2.238 a share. Its operating margin is 31.79%, which ranks better than 95% of the companies in Drug Manufacturers industry. Overall, GuruFocus ranks the profitability of Roche Holding AG at 8 out of 10, which indicates strong profitability. This is the revenue and net income of Roche Holding AG over the past years:

Roche Holding AG Stock Is Believed To Be Fairly Valued
Roche Holding AG Stock Is Believed To Be Fairly Valued

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term stock performance of a company. A faster growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of Roche Holding AG is 2.8%, which ranks in the middle range of the companies in Drug Manufacturers industry. The 3-year average EBITDA growth rate is 10.7%, which ranks in the middle range of the companies in Drug Manufacturers industry.

Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Roche Holding AG's return on invested capital is 22.61, and its cost of capital is 4.05. The historical ROIC vs WACC comparison of Roche Holding AG is shown below:

Roche Holding AG Stock Is Believed To Be Fairly Valued
Roche Holding AG Stock Is Believed To Be Fairly Valued

In closing, Roche Holding AG (OTCPK:RHHBY, 30-year Financials) stock gives every indication of being fairly valued. The company's financial condition is fair and its profitability is strong. Its growth ranks in the middle range of the companies in Drug Manufacturers industry. To learn more about Roche Holding AG stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

This article first appeared on GuruFocus.